NovImmune is interested in the possibility of in-licensing from pharmaceutical or biotechnology companies selected proprietary targets for fully human therapeutic monoclonal antibodies, preferably in the field of inflammation and immune-related diseases.

Out licensing

NovImmune’s MHC Class II inhibitors programme will lead to a novel class of low molecular immunosuppressor and anti-inflammatory agents. NovImmune is interested in partnerships for out licensing lead optimization candidates and/or in vivo leads.

For In licensing and Out licensing opportunities, please contact busdev@novimmune.com.